A Phase I/II Study of Pomalidomide (CC-4047), Dexamethasone and Romidepsin in Patients With Relapsed or Refractory Multiple Myeloma (Romi Poma)
Latest Information Update: 02 Feb 2018
At a glance
- Drugs Pomalidomide (Primary) ; Romidepsin (Primary) ; Dexamethasone
- Indications Multiple myeloma
- Focus Adverse reactions; Therapeutic Use
- Acronyms Romi Poma
- Sponsors Celgene Corporation
- 02 Jan 2018 Status changed from completed to discontinued due to losing financial support, and enrollment challenges
- 07 Feb 2017 Status changed from recruiting to completed.
- 17 Nov 2013 New trial record